ScholarLens Back to search
1992•Hämatologie und BluttransfusionRequires access

Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results

Dutch Hematologie-Oncologie Vereniging Volwassenen Nederland (HOVON), Simon Daenen, Bob Löwenberg, Pieter Sonneveld, G. Verhoeff, R. Huygen, Leo F. Verdonck

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Mitoxantrone, Daunorubicin, Cytosine, Refractory (planetary science), Amsacrine, Cytarabine, Medicine, Myeloid leukemia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results — Research Paper | ScholarLens